Pacira Pharmaceuticals, Inc. (PCRX)

Company Description

Pacira Pharmaceuticals is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, EXPAREL® (bupivacaine liposome injectable suspension), was commercially launched in the US in April 2012. EXPAREL and two other products have utilized the PCRX proprietary product delivery technology DepoFoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.


5 Sylvan Way
Parsippany, NJ 07054
United States

973-254 3560


Get BioInvest's perspective on Pacira's CEO

Latest Company News

Reading the Tea Leaves for Pacira Pharmaceuticals, Inc. (PCRX) Economic News - Aug 17, 2017 Over the last few days fluctuation in the stock of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) was the main talking point of investors. Trading Radar: Checking Technicals for Pacira Pharmaceuticals Inc (PCRX) - The Standard [...]
Thu, Aug 17, 2017 2:26:00 PM, Continue reading at the source
Traders Take Note: Pacira Pharmaceuticals Inc (NASDAQ:PCRX) Stock Drops ... CML News - Aug 15, 2017 Take Note: Pacira Pharmaceuticals Inc (NASDAQ:PCRX) has hit some technical weakness in its momentum, and while it has not broken down all the way through support -- watch the key levels that we discuss below and further, watch the stochastics and ... [...]
Tue, Aug 15, 2017 8:15:00 PM, Continue reading at the source
Pacira Pharmaceuticals, Inc. (PCRX) vs. Flexion Therapeutics, Inc. (FLXN ... StockNewsGazette - Aug 15, 2017 Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) and Flexion Therapeutics, Inc. (NASDAQ:FLXN) are the two most active stocks in the Drugs - Generic industry based on today's trading volumes. Bank of Montreal Can Sells 1172 Shares of Flexion Therapeutics, Inc. (FLXN) - StockNewsTimes [...]
Tue, Aug 15, 2017 3:45:00 PM, Continue reading at the source
Pacira Pharmaceuticals Focuses on Exparel's Label Expansion Nasdaq - Aug 14, 2017 Notably, the company's flagship product, Exparel, was launched in 2012. This product is a liposome injection of bupivacaine, which is indicated for single-dose administration into the surgical site to produce postsurgical analgesia. [...]
Mon, Aug 14, 2017 2:03:00 PM, Continue reading at the source
Option Trading: Buy or Sell Straddles in Pacira Pharmaceuticals Inc (NASDAQ:PCRX) CML News - Aug 12, 2017 As we look at Pacira Pharmaceuticals Inc we note that deciding whether to buy or sell options (in this case a straddle) is probably the most important question when it comes to option trading. [...]
Sat, Aug 12, 2017 12:36:00 PM, Continue reading at the source
Generic Drugs Stock Performance Review -- Pacira Pharma, Eagle Pharma, Neos ... Markets Insider - Aug 11, 2017 Today, takes note of the most recent performances of Pacira Pharmaceuticals Inc. (NASDAQ: PCRX), Eagle Pharmaceuticals Inc. (NASDAQ: EGRX), Neos Therapeutics Inc. (NASDAQ: NEOS), and Zynerba Pharmaceuticals Inc. [...]
Fri, Aug 11, 2017 10:18:00 AM, Continue reading at the source
Pacira Pharmaceuticals, Inc. Reports Second Quarter 2017 Financial Results Nasdaq - Aug 2, 2017 PARSIPPANY, N.J., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced consolidated financial results for the second quarter ended June 30, 2017. Why to Keeping Eye on Pacira Pharmaceuticals, Inc. (PCRX), Geron Corporation ... - StockNewsJournal Pacira Pharmaceuticals (PCRX) Q2 2017 Results - Earnings Call Transcript - Seeking Alpha [...]
Wed, Aug 02, 2017 11:26:00 AM, Continue reading at the source
How Does Pacira Pharmaceuticals, Inc. (PCRX) Stack Up Right Now? StockNewsJournal - Jul 27, 2017 Pacira Pharmaceuticals, Inc. (PCRX) is an interesting player in the Healthcare space, with a focus on Drugs - Generic. Pacira Pharmaceuticals Inc. (PCRX) Moves Lower on Volume Spike for July 27 - EPS Growth overview of Pacira Pharmaceuticals, Inc. (PCRX) - FactsReporter [...]
Thu, Jul 27, 2017 2:15:00 PM, Continue reading at the source
Pacira's Exparel Expansion Pain Continues Seeking Alpha - Jul 26, 2017 After a tortuous development process, Pacira (NASDAQ:PCRX) managed to secure US approval for Exparel in postsurgical anesthesia in 2011, but an important extension - use of the drug as a nerve block - was hit by a complete response letter three years ... Stock Update (NASDAQ:PCRX): Pacira Pharmaceuticals Inc Publishes Phase 4 ... - Smarter Analyst [...]
Wed, Jul 26, 2017 6:33:00 PM, Continue reading at the source
Pacira Pharmaceuticals Announces Timing for Second Quarter 2017 Financial ... Nasdaq - Jul 25, 2017 PARSIPPANY, N.J., July 25, 2017 (GLOBE NEWSWIRE) -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results before the open of the U.S. Pacira Pharmaceuticals Inc. (PCRX) Plunges 12.42% on July 25 - Brokers Recommendations on: Pacira Pharmaceuticals, Inc. (PCRX) - FactsReporter [...]
Tue, Jul 25, 2017 9:00:00 PM, Continue reading at the source